LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy Subjects
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 15
- Registration Number
- NCT01211964
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 244
- Registration Number
- NCT01195831
- Locations
- 🇨🇳
Bei Jing Hospital Affiliated Ministry of Health, Beijing, China
🇨🇳Second Hospital Affiliated to Medical College of Zhe Jiang University, Hangzhou, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
- Conditions
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 1152
- Registration Number
- NCT01188928
- Locations
- 🇺🇸
Horizon Research Group, Inc, Mobile, Alabama, United States
🇺🇸Advanced Clinical Research Institute, Anaheim, California, United States
🇺🇸DBA Torrance Clinical Research, Lomita, California, United States
LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 72
- Registration Number
- NCT01167309
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
🇵🇱Centralny Szpital Kliniczny MON, Warszawa, Poland
LEO 27847 - Single Dose Bioavailability Study of Oral Solution Versus Tablet in Healthy Subjects
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT01143298
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 25
- Registration Number
- NCT01141179
- Locations
- 🇨🇦
Anapharm, Toronto, Ontario, Canada
Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 900
- Registration Number
- NCT01130025
- Locations
- 🇨🇦
Diamond Health Care Centre, Vancouver, British Columbia, Canada
Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 78
- Registration Number
- NCT01120223
- Locations
- 🇨🇦
Royal University Hospital, Division of Dermatology, Saskatoon, Saskatchewan, Canada
🇨🇦Winnipeg Clinic Dermatology Research, Winnipeg, Manitoba, Canada
🇫🇷CHU Saint-Etienne - Hôpital Nord, Service de Dermatologie, Saint-Etienne, France
A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 63
- Registration Number
- NCT01116895
- Locations
- 🇫🇷
Hôpital Saint-Louis, Service de Dermatologie, Paris, France
🇨🇦Centre de Recherche Dermatologique du Quebec Metropolitain, Québec, Canada
An Irritation Study With New Calcipotriol Ointment Formulations in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01105234
- Locations
- 🇫🇷
LEO Pharma site, Nice, France